Analysts See $-0.11 EPS for Cancer Genetics, Inc. (CGIX)

March 21, 2018 - By Kurt Siggers

 Analysts See $ 0.11 EPS for Cancer Genetics, Inc. (CGIX)
Investors sentiment decreased to 0.57 in 2017 Q3. Its down 0.60, from 1.17 in 2017Q2. It dived, as 5 investors sold Cancer Genetics, Inc. shares while 9 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.58 million shares or 6.28% less from 2.76 million shares in 2017Q2 were reported.
New York-based Renaissance Tech Limited Liability has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Hrt Fincl Ltd Llc, New York-based fund reported 15,301 shares. Diker Mgmt Ltd Liability Corp has invested 0.07% in Cancer Genetics, Inc. (NASDAQ:CGIX). Barclays Public Limited Com reported 454 shares. The Virginia-based Thompson Davis & has invested 0.22% in Cancer Genetics, Inc. (NASDAQ:CGIX). Moreover, Blackrock has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX) for 40,734 shares. Jacobs Levy Equity Management has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX) for 40,158 shares. Perkins Mgmt accumulated 806,700 shares. Virtu Financial Llc owns 18,600 shares. Geode Capital Management Limited Liability Com accumulated 0% or 87,279 shares. Morgan Stanley accumulated 0% or 17,998 shares. Northern accumulated 0% or 34,771 shares. Wells Fargo & Communication Mn stated it has 0% of its portfolio in Cancer Genetics, Inc. (NASDAQ:CGIX). 809 are owned by Royal Fincl Bank Of Canada. Granahan Management Ma accumulated 237,431 shares.

Since December 15, 2017, it had 1 buying transaction, and 0 sales for $24,339 activity.

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.11 EPS on March, 22.They anticipate $0.04 EPS change or 26.67 % from last quarter’s $-0.15 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.’s analysts see -31.25 % EPS growth. The stock decreased 2.63% or $0.05 during the last trading session, reaching $1.85. About 83,828 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has risen 81.82% since March 21, 2017 and is uptrending. It has outperformed by 65.12% the S&P500.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Among 7 analysts covering Cancer Genetics (NASDAQ:CGIX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Cancer Genetics has $8 highest and $6.0 lowest target. $6.40’s average target is 245.95% above currents $1.85 stock price. Cancer Genetics had 11 analyst reports since March 11, 2016 according to SRatingsIntel. As per Thursday, September 21, the company rating was maintained by H.C. Wainwright. As per Monday, September 26, the company rating was initiated by Rodman & Renshaw. H.C. Wainwright maintained Cancer Genetics, Inc. (NASDAQ:CGIX) on Tuesday, January 16 with “Buy” rating. Maxim Group initiated the stock with “Buy” rating in Thursday, December 7 report. As per Tuesday, March 15, the company rating was maintained by Aegis Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, February 6. The stock has “Buy” rating by H.C. Wainwright on Tuesday, August 15. Janney Capital downgraded the stock to “Neutral” rating in Friday, March 11 report. H.C. Wainwright maintained Cancer Genetics, Inc. (NASDAQ:CGIX) on Wednesday, November 29 with “Buy” rating.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $44.87 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.